Informations générales (source: ClinicalTrials.gov)
Gustave Roussy Cancer Profiling
Interventional
N/A
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
mai 2021
mai 2033
13 septembre 2025
The objective of STING study is to perform high throughput molecular analysis (next
generation sequencing +/- immunological profiling) to estimate the proportion of patients
with cancer presenting at least one targetable genomic alteration.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Antoine ITALIANO | 28/06/2024 09:25:12 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| GH PARIS SITE SAINT JOSEPH | Charles NALTET, Dr | Contact (sur clinicalTrials) | |||
| HOPITAL FOCH | Alexandra BIZOT, Dr | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôpital Marie-Lannelongue - 92350 - Le Plessis-Robinson - France | Olaf MERCIER, Pr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Age ≥ 18 years
2. Histology: solid malignant tumor or hematological malignancy.
3. Patient with a social security in compliance with the French law relating to
biomedical research (Article L.1121-11 of French Public Health Code)
4. Voluntary signed and dated written informed consent prior to any study specific
procedure.
1. Age ≥ 18 years
2. Histology: solid malignant tumor or hematological malignancy.
3. Patient with a social security in compliance with the French law relating to
biomedical research (Article L.1121-11 of French Public Health Code)
4. Voluntary signed and dated written informed consent prior to any study specific
procedure.
1. Any condition which in the Investigator's opinion makes it undesirable for the
subject to participate in a clinical trial or which would jeopardize compliance with
the protocol
2. Patient under guardianship or deprived of his liberty by a judicial or
administrative decision or incapable of giving its consent
3. Pregnant or breast-feeding women
4. Minors (Age < 18 years)